�x���¹�������ֱ�ӳ���
�gӭ���R�ЈD�W(w��ng) Ո | ע��

���] ������ˎ���[-2014���

�����磺�Ї��t(y��)ˎ�Ƽ�����������r�g��2017-01-01
�_���� 32�_ 퓔�(sh��)�� 706
�� �D �r:¥385.0(5.5��) ���r  ¥700.0 ��䛺�ɿ������T�r
����ُ��܇ �ղ�
�_������ ȫ�����]
?�½������س���
������Ǖ�����>

������ˎ���[-2014��� ���(qu��n)��Ϣ

������ˎ���[-2014��� ��(n��i)�ݺ���

�������w��2014��31��ȫ�������»��W(xu��)���w���R��ǰ���Č�򞔵(sh��)��(j��)���������ϳɡ�ˎ��W(xu��)��ˎ�������W(xu��)�Ͷ���W(xu��)�������Ї����҈F꠾�����ȫӢ��׫����

������ˎ���[-2014��� Ŀ�

Executive SummaryCHAPTER1��Alectinib HydrochlorideCHAPTER2��Apatinib MesylateCHAPTER3��ApremilastCHAPTER4.AsunaprevirCHAPTER5��AtalurenCHAPTER6��BelinostatCHAPTER7��CeritinibCHAPTER8��ChidamideCHAPTER9��Daclatasvir DihydrochlorideCHAPTER10��DelamanidCHAPTER11��EliglustatTartrateCHAPTER12��EmpagliflozinCHAPTER13��FinafloxacinCHAPTER14��IdelalisibCHAPTER15��IpragliflozinL��ProlineCHAPTER16��Luseogliflozin HydrateCHAPTER17��Naloxegol OxalateCHAPTER18��Nintedanib EsylateCHAPTER19��OlaparibCHAPTER20��Oritavancin DiphosphateCHAPTER21��PhenothrinCHAPTER22��Ripasudil Hydrochloride HyrdrateCHAPTER23��SuvorexantCHAPTER24��TasimelteonCHAPTER25��TavaboroleCHAPTER26��Tedizolid PhosphateCHAPTER27��Tofogliflozin HydrateCHAPTER28��Umeclidinium BromideCHAPTER29��VaniprevirCHAPTER30��VonoprazanFumarateCHAPTER31��VorapaxarSulfateAppendix.AbbreviationAppendixII.SalesWorldwider2014��2015)AppendixIII.WorldwideApproved NCEs(2001��2015)Append&IV.WorldwideApproved NCEs(SortedbyIndication2001��2015)
��Ʒ�uՓ(0�l)
���o�uՓ����
�������]
����N
����픲�
�ЈD�W(w��ng)
�ھ��ͷ�